Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)

NCT ID: NCT01914562

Last Updated: 2014-08-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2013-11-30

Brief Summary

This is an open label, randomized, balanced, single center, single dose, trial to assess the pharmacokinetic (PK) profile of OCA, glyco-OCA and tauro-OCA on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence, crossover manner.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

OCA 10 mg while fasted

OCA 10 mg orally in the fasting state

Group Type: EXPERIMENTAL

OCA 10 mg

Intervention Type: DRUG

OCA 10 mg tablet oral

OCA 10 mg while Fed

OCA 10 mg orally in the fed state

Group Type: EXPERIMENTAL

OCA 10 mg

Intervention Type: DRUG

OCA 10 mg tablet oral

OCA 25 mg while fasted

OCA 25 mg orally in the fasting state

Group Type: EXPERIMENTAL

OCA 25 mg

Intervention Type: DRUG

OCA 25 mg tablet oral

OCA 25 mg while Fed

OCA 25 mg orally in the fed state

Group Type: EXPERIMENTAL

OCA 25 mg

Intervention Type: DRUG

OCA 25 mg tablet oral

Interventions

OCA 10 mg

OCA 10 mg tablet oral

Intervention Type: DRUG

OCA 25 mg

OCA 25 mg tablet oral

Intervention Type: DRUG

Other Intervention Names

6α-ethyl chenodeoxycholic acid;(6-ECDCA), INT-747; 6α-ethyl chenodeoxycholic acid;(6-ECDCA), INT-747

Eligibility Criteria

Inclusion Criteria

Subjects are required to meet the following criteria in order to be included in the trial.

1. Male or female subjects from 18 to 55 years

2. Contraception: Female subjects must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use more than 1 effective (≤ 1% failure rate) method of contraception during the trial and until at least 30 days after the last dose of OCA. Effective methods of contraception are considered to be:

1. Double barrier method, ie, (a) condom (male or female) with spermicide or (b) diaphragm with spermicide

2. Intrauterine device (IUD)

3. Vasectomy

3. Good general health as determined by medical history, and by results of physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests obtained within 14 days prior to Day 0

4. Body mass index (BMI) of 18 to 28; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).

5. Willing to abstain from alcohol, caffeine, and xanthine-containing food and beverages for 72 hours prior to each period check in and during participation of the inpatient periods of the trial

6. Willing and able to give written informed consent

Exclusion Criteria

Subjects meeting the following criteria will be excluded from the trial.

1. Prior participation in a clinical trial of OCA (INT-747; 6-ECDCA)

2. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease

3. History of gastrointestinal surgeries or gall bladder removal (cholecystectomy)

4. History or presence of a clinically significant cardiovascular, hepatic, diabetic, gastrointestinal, metabolic, neurologic, pulmonary, endocrine, psychiatric, or neoplastic disorder(s)

5. History of known or suspected clinically significant hypersensitivity to any drug, aside from penicillin

6. Ingestion of a prescription medication within 14 days prior to Day 0 or ingestion of an over the counter medication within 7 days prior to Day 0

7. Participation in radiologic examinations involving parenteral administration of iodinated contrast materials within 2 weeks prior to screening, or subsequently, through the end of trial participation

8. History or presence of alcohol abuse (defined as consumption of more than 210 mL of alcohol per week; or the equivalent of fourteen 4 ounces (oz) glasses of wine, or fourteen 12 oz cans/bottles of beer or wine coolers per week)

9. History or presence of substance abuse within the past 2 years or positive drug screen tests

10. Smoker or user of tobacco or nicotine products

11. Any screening laboratory test for which the results are not within the normal reference range and considered clinically significant

12. Participation in another investigational drug trial within 30 days prior to Day 0

13. History of noncompliance to medical regimens, or subjects who are considered to be potentially unreliable

14. Blood or plasma donation within 30 days prior to Day 0

15. Mental instability or incompetence

16. Presence of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) at screening

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Intercept Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Shapiro, MD

Role: STUDY_DIRECTOR

Intercept Pharmaceticals, Inc.

Terry E. O'Reilly, MD

Role: PRINCIPAL_INVESTIGATOR

Celrion, Inc.

Locations

Celerion, Inc.

Tempe, Arizona, United States

Countries

United States

Other Identifiers

747-104

Identifier Type: -

Identifier Source: org_study_id